Lupus Unmasked: The Infliximab Connection

Author(s)	Angelin Susan Varghese, Dr. Kavya Annie Rojin, Dr. Mathew Anil Chempakasseril, Dr. Vishnu S Chandran, Dr. Sara Kurien Kodiattu
Country	India
Abstract	Drug-induced lupus erythematosus (DILE) is an autoimmune phenomenon where the symptoms are similar to systemic lupus erythematosus (SLE) after exposure to certain drugs. While DILE tends to be less severe than SLE, the diagnosis can be challenging. Infliximab, a TNF-alpha inhibitor, is widely prescribed for autoimmune conditions such as Crohn’s disease, rheumatoid arthritis, and ankylosing spondylitis. Although rare, Infliximab can cause Drug-Induced Lupus Erythematosus (DILE). This case report presents a 67-year-old male patient who developed this unconventional adverse drug reaction. It emphasizes the importance of vigilant monitoring, early detection, and prompt intervention to prevent long-term complications in patients receiving Infliximab treatment.
Keywords	Systemic Lupus Erythematosus, Infliximab, TNF-alpha Inhibitor, Rheumatoid arthritis, Adverse drug reaction, Drug Induced Lupus Erythematosus (DILE)
Field	Medical / Pharmacy
Published In	Volume 7, Issue 3, May-June 2025
Published On	2025-06-28
DOI	https://doi.org/10.36948/ijfmr.2025.v07i03.47026
Short DOI	https://doi.org/g9rnxn

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research